105 related articles for article (PubMed ID: 6616494)
41. A design for phase II testing of anticancer agents within a phase III clinical trial.
Schaid DJ; Ingle JN; Wieand S; Ahmann DL
Control Clin Trials; 1988 Jun; 9(2):107-18. PubMed ID: 3396362
[TBL] [Abstract][Full Text] [Related]
42. A new weapon in the technology transfer arsenal: a clinical research/patient decision support system for microcomputers.
Mortenson LE; Thompson JR
Prog Clin Biol Res; 1984; 156():379-96. PubMed ID: 6382321
[No Abstract] [Full Text] [Related]
43. Historical and methodological developments in clinical trials at the National Cancer Institute.
Gehan EA; Schneiderman MA
Stat Med; 1990 Aug; 9(8):871-80; discussion 903-6. PubMed ID: 2218190
[TBL] [Abstract][Full Text] [Related]
44. KSTAGE: an interactive computer program for designing phase II clinical trials using predictive probability.
Atkinson EN; Brown BW; Herson J
Comput Biomed Res; 1982 Jun; 15(3):220-7. PubMed ID: 7105670
[No Abstract] [Full Text] [Related]
45. APL programs for outcome probabilities and confidence limits in sequential binomial trials.
Larsen SO
Control Clin Trials; 1984 Sep; 5(3):245-9. PubMed ID: 6548431
[TBL] [Abstract][Full Text] [Related]
46. Clinical trial procedures clarified.
Zimmerman JF
Oncol Nurs Forum; 1990; 17(5):661. PubMed ID: 2251182
[No Abstract] [Full Text] [Related]
47. The analysis of titration studies in phase III clinical trials.
Shih WJ; Gould AL; Hwang IK
Stat Med; 1989 May; 8(5):583-91. PubMed ID: 2727477
[TBL] [Abstract][Full Text] [Related]
48. Logistics of therapeutic trials: the example of cancerology.
Mathé G; Kenis Y
Biomedicine; 1973 May; 18(3):181-4. PubMed ID: 4742859
[No Abstract] [Full Text] [Related]
49. A FORTRAN program for the design and analysis of sequential clinical trials.
Whitehead J; Marek P
Comput Biomed Res; 1985 Apr; 18(2):176-83. PubMed ID: 3838715
[TBL] [Abstract][Full Text] [Related]
50. Monitoring clinical trials: conditional or predictive power?
Spiegelhalter DJ; Freedman LS; Blackburn PR
Control Clin Trials; 1986 Mar; 7(1):8-17. PubMed ID: 3956212
[TBL] [Abstract][Full Text] [Related]
51. Letter: Assessment of papers of clinical trials.
Nyberg G
Med J Aust; 1974 Sep; 2(10):381. PubMed ID: 4608038
[No Abstract] [Full Text] [Related]
52. Perspectives on the statistician's role in cooperative clinical research.
Breslow N
Cancer; 1978 Jan; 41(1):326-32. PubMed ID: 342084
[TBL] [Abstract][Full Text] [Related]
53. Sample sizes for phase II and phase III clinical trials: an integrated approach.
Whitehead J
Stat Med; 1986; 5(5):459-64. PubMed ID: 3787000
[TBL] [Abstract][Full Text] [Related]
54. The use of prior information in the testing of new drugs.
Allen DM
Biometrics; 1971 Sep; 27(3):699-708. PubMed ID: 4940382
[No Abstract] [Full Text] [Related]
55. [Early interruption of a clinical trial: rationale and interpretation].
Savonitto S; De Servi S; Maggioni AP; Cesana BM
G Ital Cardiol (Rome); 2019 Nov; 20(11):619-626. PubMed ID: 31697268
[TBL] [Abstract][Full Text] [Related]
56. Volume doubling approach to tumor measurement.
Spears CP
J Clin Oncol; 1985 Nov; 3(11):1563. PubMed ID: 4056847
[No Abstract] [Full Text] [Related]
57. Improving clinical trials with the help of the computer [proceedings].
Burdock EI
Psychopharmacol Bull; 1979 Apr; 15(2):33-5. PubMed ID: 432370
[No Abstract] [Full Text] [Related]
58. Optimal phase II trials.
Weiss GB; Hokanson JA
Biometrics; 1988 Sep; 44(3):910-1. PubMed ID: 3203136
[No Abstract] [Full Text] [Related]
59. A computer program for the analysis of crossover designs.
Gaines Das RE; Hughes MR
Comput Programs Biomed; 1979 Sep; 10(2):105-13. PubMed ID: 487777
[TBL] [Abstract][Full Text] [Related]
60. Computer simulation as a tool for clinical trial design.
Jones DR
Int J Biomed Comput; 1979 Mar; 10(2):145-50. PubMed ID: 489149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
